Department of Oncology and Radiotherapy, University Hospital Split, School of Medicine, University of Split.
Acta Clin Croat. 2022 Oct;61(Suppl 3):81-85. doi: 10.20471/acc.2022.61.s3.12.
For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC.
多年来，雄激素剥夺疗法（ADT）单药治疗一直是转移性激素敏感前列腺癌（mHSPC）治疗的金标准。过去十年中发表的多项研究表明，与 ADT 单药治疗相比，联合标准 ADT 加多西他赛或雄激素受体靶向治疗（ARTA）治疗可显著提高生存率。最近发表的 PEACE-1 和 ARASENS 试验数据表明，未来，三联疗法可能是 mHSPC 患者的一种治疗选择。
